锥束ct
影像引导放射治疗
核医学
放射治疗计划
磁共振成像
冠状面
计算机断层摄影术
放射治疗
医学
锥束ct
放射科
作者
Bao Wan,Lee Joycelyn Jie Xin,Yanxin Zhang,Deqi Chen,Zhuoran Li,Yuan Zong,Bofei Liu,Wenhua Qin,Zhiwei Zhang,Yongtai Zheng,Yirui Zhai,Bin Chen
出处
期刊:Research Square - Research Square
日期:2023-11-08
标识
DOI:10.21203/rs.3.rs-3499085/v1
摘要
Abstract Background and purpose To compare the setup errors and the clinical target volume (CTV) to planning target volume (PTV) margins in image-guided radiotherapy (IGRT) for liver cancer using three-dimensional cone beam computed tomography (3DCBCT) and four-dimensional cone beam computed tomography (4DCBCT), and explore the advantages of 4DCBCT for the position verification in liver cancer irradiation. Materials and methods Fifty-five patients with liver cancer were enrolled. All patients’ CT, four-dimensional computed tomography (4DCT) and Magnetic Resonance (MR) simulation images were collected. Image registration, target delineation, and plan design were accomplished in Pinnacle treatment planning system. Pre-treatment’s 3DCBCT and 4DCBCT images were collected at a certain frequency and registered with the simulation CT images. Before beam delivery, the therapy couch was corrected based on the setup errors measured by 4DCBCT. Investigators recorded the setup errors and calculated the CTV to PTV margins using van Herk’s formula. Paired t-test was used to compare the difference of the two groups. Results A total of 452 sets of 3DCBCT and 4DCBCT images were collected. The setup errors in 4DCBCT group in superior-inferior (S-I) direction, anterior-posterior (A-P) direction, transverse plane, and coronal plane were significant smaller than in 3DCBCT group, which were 2.6 ± 4.8 mm and 2.1 ± 4.0 mm, P < 0.001; 1.8 ± 1.9 mm and 1.4 ± 1.7 mm, P < 0.001; 0.80 ± 0.76° and 0.75 ± 0.61°, P < 0.001; 0.90 ± 0.74° and 0.78 ± 0.75°, P < 0.001. And the CTV-PTV margins in three-dimensional directions are (5.7, 9.8, 5.8) mm and (5.1, 8.0, 4.6) mm, respectively. Conclusion 4DCBCT is superior to 3DCBCT in monitoring setup errors and supports smaller PTV margins for liver cancer radiotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI